Consistent with the in vitro results, orally administered WBC100 twice a day for 20 d exerted dose‐dependent antitumor activity in human c‐Myc overexpressing AML in NSG mice (Figure 5A). This evidence concerns the gene MYC and acute myeloid leukemia.